Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3CNS 2Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Pancreatic Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Neoplasms 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 69Fluorouracil 44pembrolizumab 43Oxaliplatin 42Capecitabine 40Bevacizumab 37Leucovorin 36Irinotecan 31Cisplatin 27Nivolumab 24Paclitaxel 21Cetuximab 21Panitumumab 20130-nm albumin-bound paclitaxel 20Sorafenib 18Albumin-Bound Paclitaxel 18Drug Therapy 15Docetaxel 15Cyclophosphamide 15Radiotherapy 14Blood Specimen Collection 14IFL protocol 12atezolizumab 11Exercise 11Taxes 10budigalimab 9Erlotinib Hydrochloride 9trametinib 8Folfox protocol 8Carboplatin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × vandetanib × Gastrointestinal × Clear all
NCT00508001 2016-10-10

Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

Sanofi

Phase 2 Completed
67 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡